KRAS-mutation positive, metastatic tonsil carcinoma with cancer stem-like cell features and long-term response to gefitinib: A case report and review of the literature

Journal of Clinical Oncology

Volumn 29, Issue 21, 2011, Pages

  Gottschling, Sandra ^a   Penzel, Roland ^b   Pelz, Tanja ^c   Herpel, Esther ^b   Schnabel, Philipp A ^b   Dyckhoff, Gerhard ^b   Thomas, Michael ^a   Kuhnt, Thomas ^d  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^d UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GEFITINIB; MITOMYCIN;

ADULT; ARTICLE; CANCER STEM CELL; CASE REPORT; DIARRHEA; DRUG DOSE REDUCTION; FEMALE; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; METASTASIS; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SQUAMOUS CELL CARCINOMA; TONSIL CARCINOMA; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; BIOPSY; CARCINOMA, SQUAMOUS CELL; FATAL OUTCOME; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MIDDLE AGED; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; QUINAZOLINES; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TONSILLAR NEOPLASMS; TREATMENT OUTCOME;

EID: 79960720751     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.34.5892     Document Type: Article

References (19)

1. Argiris A, Karamouzis MV, Raben D, et al: Head and neck cancer. Lancet 371:1695-1709, 2008 (Pubitemid 351671886)
2. Ang KK, Harris J, Wheeler R, et al: Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363:24-35, 2010
3. Kalyankrishna S, Grandis JR: Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 24:2666-2672, 2006 (Pubitemid 46622088)
4. Cohen EE, Haraf DJ, Kunnavakkam R, et al: Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 28:3336-3343, 2010
5. AstraZeneca: Clinical trials: All drug products. http://www. astrazenecaclinicaltrials.com/drug-products/drugproducts/?itemld=8574321
6. Cohen EE: Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 24:2659-2665, 2006
7. Cohen EE, Kane MA, List MA, et al: Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 11:8418-8424, 2005 (Pubitemid 41746956)
8. Cohen EE, Rosen F, Stadler WM, et al: Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 21:1980-1987, 2003
9. Soulieres D, Senzer NN, Vokes EE, et al: Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 22:77-85, 2004 (Pubitemid 41095117)
10. Stewart JS, Cohen EE, Licitra L, et al: Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 27:1864-1871, 2009
11. Loeffler-Ragg J, Witsch-Baumgartner M, Tzankov A, et al: Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma. Eur J Cancer 42:109-111, 2006 (Pubitemid 41814540)
12. Van Damme N, Deron P, Van Roy N, et al: Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas. BMC Cancer 10:189, 2010
13. Ang KK, Berkey BA, Tu X, et al: Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62:7350-7356, 2002 (Pubitemid 36025259)
14. Temam S, Kawaguchi H, El-Naggar AK, et al: Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 25:2164-2170, 2007 (Pubitemid 46954638)
15. Zhang Q, Shi S, Yen Y, et al: A subpopulation of CD133(+) cancer stem-like cells characterized in human oral squamous cell carcinoma confer resistance to chemotherapy. Cancer Lett 289:151-160, 2010
16. Okamoto A, Chikamatsu K, Sakakura K, et al: Expansion and characterization of cancer stem-like cells in squamous cell carcinoma of the head and neck. Oral Oncol 45:633-639, 2009
17. Chen JS, Pardo FS, Wang-Rodriguez J, et al: EGFR regulates the side population in head and neck squamous cell carcinoma. Laryngoscope 116:401-406, 2006 (Pubitemid 44318100)
18. Li J, Cusatis G, Brahmer J, et al: Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biol Ther 6:432-438, 2007 (Pubitemid 47328313)
19. Griffero F, Daga A, Marubbi D, et al: Different response of human glioma tumor-initiating cells to epidermal growth factor receptor kinase inhibitors. J Biol Chem 284:7138-7148, 2009